Glioblastoma | Treatment | Immunotherapy | Tumor-infiltrating lymphocytes



	Topics
	Glioblastoma \| Treatment \| Immunotherapy \| Tumor-infiltrating lymphocytes

	Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Tumor-infiltrating lymphocytes


1999
AA	Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, Gudeman S, Varia MA. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol. 1999 Nov;45(2):141-57. doi: 10.1023/a:1006293606710. PMID: 10778730. Trial registration ID: NA. ˍ


2002
ME	Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002 Sep 19;298(5594):850-4. doi: 10.1126/science.1076514. PMID: 12242449. Trial registration ID: NA. ˍ


2017
	Liu Z, Meng Q, Bartek J Jr, Poiret T, Persson O, Rane L, Rangelova E, Illies C, Peredo IH, Luo X, Rao MV, Robertson RA, Dodoo E, Maeurer M. Tumor-infiltrating lymphocytes (TILs) from patients with glioma. Oncoimmunology. 2017 Feb 8;6(2):e1252894. doi: 10.1080/2162402X.2016.1252894. PMID: 28344863. ˍ


2018
	Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018 Sep 4;24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846. PMID: 29437767. ˍ


2025
	Lucas C M Arruda, Julia Karbach, Dragan Kiselicki, Hans-Michael Altmannsberger, Evgueni Sinelnikov, Dirk Gustavus, Hans Hoffmeister, Akin Atmaca, Elke Jäger. Tumor-infiltrating lymphocytes-derived CD8 clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025 Apr 25;85(8_Suppl_2):Abstract nr LB370. doi: 10.1158/1538-7445.AM2025-LB370. ˍ

	Maffezzini M, Musio S, Di Ianni N, Rumolo A, Patanè M, Galluzzo A, Sambruni I, Berlendis A, Aquino D, Baso G, Zingarelli M, Facciolla M, Maddaloni L, Valentino R, Paterra R, Agistri F, Farinotti M, Mattei L, Coluccia P, Acerbi F, DiMeco F, Pollo B, Silvani A, Eoli M, Traversari C, Montagna D, Pellegatta S. Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy. Nat Commun. 2025 Aug 25;16(1):7279. doi: 10.1038/s41467-025-62263-2. PMID: 40855052. ˍ

	Arruda LCM, Karbach J, Kiselicki D, Altmannsberger HM, Sinelnikov E, Gustavus D, Hoffmeister H, Atmaca A, Jäger E. Tumor-infiltrating lymphocytes-derived CD8⁺ clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma. Oncoimmunology. 2025 Oct 7;14(1):2559784. doi: 10.1080/2162402X.2025.2559784. PMID: 41054926. ˍ

	Chen Y, Ma X, Cheng Y, Zhuang W, Jin H, Lan Q. 536 Phase 1 trial of tumor-infiltrating lymphocyte (TIL) therapy in recurrent glioblastoma: A single-center experience using cells derived from primary surgical specimens [abstract]. J Immunother Cancer. 2025 Nov 4;13(Suppl 2):536. Trial registration ID: NCT04943913. ˍ

	Pristo EL, Hotchkiss KM, Corcoran AM, Noldner P, Okada H, Hickey JW, Conejo-Garcia J, Shaz B, Khasraw M. The promise of TIL therapy for glioblastoma. Trends Cancer. 2025 Nov 13:S2405-8033(25)00254-7. doi: 10.1016/j.trecan.2025.10.003. PMID: 41238472. Review˰ ˍ


2026
	Prafulla C. Gokhale, David A. Reardon, Friedrich Erhart, Georg Widhalm, Benjamin K. Eschle, Brittaney Leeper, Maia Lineberry, Romana Gugenberger, Alexander Dohnal, Mario Kuttke. Ex vivo Cbl-b silenced, autologous TIL therapy in glioblastoma demonstrates proof-of-concept efficacy and translational potential [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Brain Cancer; 2026 Mar 23-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026 Mar 23;86(6_Suppl):Abstract nr A033. doi: 10.1158/1538-7445.BRAIN26-A033. ˍ

	Hill CM, Nwagwu CD, Odukoya AO, Hsueh B, Wang AZ, Dunn GP. Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications. NPJ Precis Oncol. 2026 Jul 13;10(1):274. doi: 10.1038/s41698-026-01330-3. PMID: 42437767. ˍ